1. Background
=============

Ductus arteriosus (DA) is a fetal vascular connection between the main pulmonary artery and the aorta that diverts blood away from the pulmonary bed. Histologically, ductal tissue differs from that of the adjacent aorta and pulmonary artery ([@A2005REF1]). The fetal DA is kept patent by low arterial oxygen content and circulating prostaglandin E2 (PGE2), which is produced in part by the placenta ([@A2005REF2]). At birth, the rise in systemic arterial oxygen tension and a decrease in circulating PGE2 levels trigger ductal constriction.

Although the mechanism that causes active ductal constriction is not known, gene transfer studies suggest that it is mediated by an oxygen-sensitive potassium channel ([@A2005REF3]). After delivery, circulating PGE2 levels fall because of reduced production following the removal of the placenta and increased PGE2 clearance due to increase in the circulating levels of prostaglandin dehydrogenase ([@A2005REF4], [@A2005REF5]). Removal of the strong vasodilatory effect of PGE2 is sensed by the PGE2 receptor (EP4) and promotes further constriction of the ductus ([@A2005REF6], [@A2005REF7]). The incidence rate of an isolated patent ductus arteriosus (PDA) among term infants has been reported to range from 0.03 to 0.08 percent ([@A2005REF8]). The hemodynamic consequences of the PDAs can be categorized by the degree of left-to-right shunting based upon the pulmonary to systemic flow ratio (Qp: Qs) ([@A2005REF9]). The diagnosis of PDA is usually based upon its clinical findings and is typically confirmed by echocardiography. Cardiac catheterization and angiography are generally only necessary when percutaneous therapy is being considered or in the context of more complex congenital heart disease.

The individuals with PDA have increased morbidity and mortality, primarily due to heart failure and rarely infective endocarditis. Additionally, pulmonary vascular disease is an uncommon problem. Also, PDA can be complicated with chronic lung disease, intraventricular hemorrhage, and necrotizing enterocolitis due to severe left to right shunt ([@A2005REF10]). Surgical or interventional closing of PDA is usually recommended after the age of 6 months. Conventional surgical closure or video-assisted thoracoscopic surgery is appropriate for the infants with a moderate to large PDA ([@A2005REF5]). Surgical ligation of the DA has been associated with increased morbidity and adverse neurodevelopmental outcome ([@A2005REF11]). Yet, a relatively higher incidence of vocal cord paralysis has been reported postoperatively in the infants with PDA ([@A2005REF12]). Some reports have shown indomethacin, a cyclooxygenase inhibitor, to be useful in closing PDA.

In our center, in a prospective case-control study, 51 neonates with PDA and gestational age of 37 weeks or more were evaluated in order to determine the effectiveness of the standard dose (10 - 5 - 5 mg/kg/day for 3 days) of oral ibuprofen. In that study, 30 neonates received ibuprofen and 21 neonates received the placebo. After 4 days of starting the medication, DA was closed in 43.3% of the case group subjects and 4.7% of the control group ones. The results of the study showed that PDA was closed more and faster in the neonates receiving oral ibuprofen compared to the control group ([@A2005REF13]).

2. Objectives
=============

According to a study that showed more and faster closure of PDA with use of high-dose ibuprofen in preterm neonates ([@A2005REF14]), we designed this study to determine whether high-dose oral ibuprofen was more effective in closing PDA in full-term neonates.

3. Patients and Methods
=======================

The present study was performed on 33 neonates with gestational age of 37 weeks or more and postnatal age of 3 to 30 days who were suffering from PDA and were admitted in the neonatal and pediatric cardiologic centers of Shiraz University of Medical Sciences. This study was designed similar to a previous study which compared the effect of oral ibuprofen on full term neonates and a control group in this neonatal center. We evaluated the effect of high dose ibuprofen in closure of PDA in term neonates. In this clinical trial, we used double dose ibuprofen (20 mg/kg, 10 mg/kg, and 10 mg/kg) for 3 - 30 day old term neonates with PDA who were admitted to the neonatal wards of University of Medical sciences. The results of this study were compared to the data of the previous study in our center which used the low dose of ibuprofen (10 mg/kg, 5 mg/kg, and 5 mg/kg) for 30 full term neonates and compared with 21 neonates who received placebo in a randomized control trial. [Figure 1](#A2005FIG1){ref-type="fig"} shows consort flow diagram of the study. The study was approved by the ethics committee of the university (code number: CT-91-6370). All the patients were diagnosed clinically by a neonatologist and confirmed by a pediatric cardiologist with echocardiography. Four neonates were excluded from the study because of death due to the associated severe medical problems before taking ibuprofen. Overall, 29 neonates (male to female ratio: 66.6%) received high dose ibuprofen (20 - 10 - 10 mg/kg/day) for 3 days, as an oral suspension (100 mg/5 mL; Hakim Pharmaceutical, Tehran, Iran, 75-HM-30). Before and after the 4th day of medication, blood urea nitrogen, creatinine, and platelet levels were measured. Additionally, the patients were monitored for oliguria, bleeding, gastrointestinal discomfort, and other side effects of ibuprofen. Echocardiography was performed with a Vivid 3 ultrasound machine (GE Vingmed, Horten, Norway) using 7 MHz probes on days one and four of the study. The neonates were also evaluated regarding the pressure gradient, size of PDA, left atrial to aortic ratio, and development of pulmonary hypertension.
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The data were recorded on a form especially designed by the neonatologist and pediatric cardiologist. Then, they were entered into the SPSS statistical software, v.18 (SPSS Inc. Chicago, IL) and analyzed using Chi-square, Kruskal-Wallis, ANOVA and, student t-tests.

4. Results
==========

The results revealed no statistically significant difference between the neonates who received high dose oral ibuprofen and those in our previous study regarding the base line demographic, paraclinical, and echocardiographic parameters, except for platelet count ([Tables 1](#A2005TBL1){ref-type="table"} and [2](#A2005TBL2){ref-type="table"}). Echocardiographic evaluation on the 4^th^ day of the treatment revealed 62.1% PDA closing. However, this measure was obtained as 43.3% in the group receiving the standard dose of oral ibuprofen and 4.7% in the placebo group in the previous study (P = 0.001, [Figure 2](#A2005FIG2){ref-type="fig"}) ([@A2005REF13]). Besides, diameter of the pulmonic end of DA decreased from 2.09 ± 0.56 mm to 0.77 ± 1.10 mm in the neonates who received high dose oral ibuprofen (P \< 0.001). In this group, the average diameter of DA decreased by 1.32 mm, while it was decreased by 0.87 mm and 0.7 mm in the neonates who received the standard dose ibuprofen and those in the control group, respectively (P = 0.046). The results demonstrated no significant correlation between the decrease in PDA size and the neonates' gestational and postnatal age. Furthermore, no significant adverse effects of ibuprofen were reported. Only two neonates had a mild feeding intolerance, but they did not need any treatment. It should also be mentioned that the same event was detected in the low dose group, as well.

###### Demographic and Para-Clinical Parameters in Neonates Who Were Treated With High Dose Ibuprofen, Standard Dose Ibuprofen and Placebo ^[a](#A2005TBL1FN1){ref-type="table-fn"}^

  Parameter                                                     High Dose Ibuprofen (n = 29)   Standard Dose Ibuprofen (n = 30)   Placebo (n = 21)   P Value
  ------------------------------------------------------------- ------------------------------ ---------------------------------- ------------------ ---------
  **Gender** ^**[b](#A2005TBL1FN2){ref-type="table-fn"}**^                                                                                           0.271
  Male                                                          12 (41.4)                      14 (46.7)                          12 (57.1)          
  Female                                                        7 (58.6)                       16 (53.3)                          9 (42.9)           
  **Age, d** ^**[c](#A2005TBL1FN3){ref-type="table-fn"}**^      7.9 ± 7.34                     10.73 ± 8.51                       10.43 ± 9.2        0.349
  **Weight, g** ^**[c](#A2005TBL1FN3){ref-type="table-fn"}**^   3172.90 ± 528.55               3368 ± 573.1                       3391.43 ± 635.27   0.313
  **Blood urea nitrogen (mg%) before treatment**                13.32 (5.22)                   16.07 (11.3)                       14.19 (6.60)       0.532
  **Blood urea nitrogen (mg%) after treatment**                 10 25 (6.54)                   15.13 (6.53)                       12.34 (11.16)      0.088
  **Creatinine (mg%) before treatment**                         0.52 (0.29)                    0.66 (0.36)                        0.71 (0.36)        0.175
  **Creatinine (mg%) after treatment**                          0.59 (0.25)                    0.57 (0.21)                        0.65 (0.31)        0.073
  **Platelet (× 1000) before treatment**                        234.530 (81.328)               162.167 (64.137)                   194.904 (22.400)   0.009
  **Platelet (× 1000) after treatment**                         257.070 (99.084)               177.714 (60.238)                   131.600 (22.400)   0.003

^a^ Placebo and standard dose data are from article published in Pediatr Cardiol 2010; 31: 40 - 43 ([@A2005REF13]).

^b^ Values are presented as No. (%).

^c^ Values are presented as mean ± SD.

###### Echocardiographic Findings in Neonates Who Were Treated With High Dose Ibuprofen, Standard Dose Ibuprofen and Placebo ^[a](#A2005TBL2FN1){ref-type="table-fn"}^

  Echocardiographic Findings                                                          High Dose Ibuprofen (n = 29)   Standard Dose Ibuprofen (n = 30)   Placebo (n = 21)   P Value
  ----------------------------------------------------------------------------------- ------------------------------ ---------------------------------- ------------------ ---------
  **Size of pulmonic end of PDA, mm** ^**[b](#A2005TBL2FN2){ref-type="table-fn"}**^   2.09 ± 0.56                    1.68 ± 0.87                        2.10 ± 0.8         0.058
  **Systolic gradient, mmHg**^**[b](#A2005TBL2FN2){ref-type="table-fn"}**^            24.2 ± 9.7                     29.3 ± 8.1                         29.5 ± 11.4        0.100
  **Diastolic gradient, mmHg** ^**[b](#A2005TBL2FN2){ref-type="table-fn"}**^          14.6 ± 4.7                     20.1 ± 6.7                         21.7 ± 9.9         0.062
  **Left atrial/Aortic ratio** ^**[b](#A2005TBL2FN2){ref-type="table-fn"}**^          1.40 ± 0.23                    1.52 ± 0.27                        1.39 ± 0.19        0.107

^a^ Placebo and standard dose data are from article published in pediatr cardiol 2010; 31:40 - 43 ([@A2005REF13]).

^b^ Values are presented as mean ± SD.
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5. Discussion
=============

The studies conducted by Gittenberger and Groot ([@A2005REF15]) showed a series of physiological changes leading to functional and anatomical PDA closing in newborns. If these changes do not occur due to duct immaturity, perinatal and postnatal problems, or ductal malformations, the DA will not be closed. The first goal of treatment of PDA in term neonates is controlling the complications (congestive heart failure). Indomethacin is the most common drug used to close PDA despite having some adverse effects on renal function. Ibuprofen is another effective cyclooxygenase inhibitor used to close PDA which is accompanied by less renal adverse effects. Traditionally, PDA in full-term newborns was surgically treated that had some morbidity. To date, some studies have been conducted on using indomethacin and ibuprofen (intravenous and oral) to treat PDA in pre-term and term neonates. McCarthy et al. ([@A2005REF16]) demonstrated the effect of indomethacin therapy on PDA in four newborn infants with birth weight of 1500 - 2075 grams that were born at the gestational age of 35 weeks or above. Moreover, Watanabe et al. ([@A2005REF17]) reported the closure of PDA in 4 out of 7 full-term infants with birth weight of 2500 gr or more that were treated with indomethacin. Another study reported a success rate of 61% in decreasing the size or closure of PDA using intra-venous indomethacin in 41 full-term neonates ([@A2005REF18]). Rudolph ([@A2005REF19]) also indicated a closure rate of approximately 80% in premature neonates after using 0.1 - 0.2 mg/kg intravenous indomethacin every 12 - 24 hours. Indomethacin, a prostaglandin synthetize inhibitor, has been shown to close the DA in a large number of premature infants up to 14 days of age and occasionally as late as one month of age. Yet, its contraindications include renal failure, active bleeding, and significant thrombocytopenia. It should be noted that failure of indomethacin therapy is mostly associated with extreme immaturity and greater postnatal age at the beginning of the therapy ([@A2005REF20]).

Thomas et al. stated that the effect of ibuprofen on closing the PDA was similar to that of indomethacin ([@A2005REF21]). In a prospective case-control study in our neonatology ward, after 4 days of starting the standard dose of oral ibuprofen in 51 full-term neonates, DA was closed in 43.3% of the case group subjects and 4.7% of the control group ones. The results also showed that PDA was closed more and faster in the full term neonates who had received oral ibuprofen ([@A2005REF13]). Moreover, high-dose ibuprofen was more effective in closure of PDA in preterm neonates ([@A2005REF14]). In the current study, we studied 29 term neonates under exactly the same conditions as the previous study, but using high dose oral ibuprofen. On the 4^th^ day after starting the treatment, 62.1% of the neonates showed PDA closure, which was statistically higher compared to the control group, but not the group receiving the standard dose of ibuprofen (P \< 0.0008). Overall, comparing the results of these two studies revealed another important aspect of treatment with ibuprofen. In our new study, the average diameter of the pulmonic end of DA changed from 2.09 mm to 0.77 mm (decreased 1.32 mm) after the treatment. However, in the previous study using the standard dose of oral ibuprofen, this change was much less (from 1.68 mm to 0.81 mm on 4^th^ day after the treatment, which is 0.87 mm). This shows that high dose oral ibuprofen may be more effective in controlling PDA symptoms. In addition, using high dose ibuprofen was not accompanied by any adverse effects.

High dose oral ibuprofen was effective in closing PDA in full-term neonates who needed treatment. In cases that PDA was not closed after low dose oral ibuprofen, the size of DA was significantly decreased following treatment with high dose ibuprofen. Therefore, we may recommend using high dose oral ibuprofen in full-term neonates with PDA before choosing the surgical approach. It can also be the first choice in the patients with large PDA to control symptoms.

5.1. Limitations of the Study
-----------------------------

Small sample size and not blinding the historical cohort of group seem to be major limitations of the study.
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